Skip to content

Tafamidis

    DAE Class; Rx

    Common Brand Names; Vyndamax

    • Cardiovascular, Other

    Selective stabilizer of transthyretin (TTR) for cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults
    Reduces cardiovascular mortality and cardiovascular-related hospitalizations
    Potential to cause fetal harm; advise women of child-bearing potential to use contraception during therapy

    Indicated for cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization

    Dosing Considerations

    Tafamidis (Vyndamax) and tafamidis meglumine (Vyndaqel) are not substitutable on a per mg basis

    Drug interactions overview

    • Breast cancer-resistant protein (BCRP) inhibitor
    • BCRP substrates
      • Monitor for signs of BCRP substrate-related toxicities and modify dosage of substrate if appropriate
      • Tafamadis increases exposure and risk of toxicities of BCRP substrates

    Pregnancy

    Based on animal studies, fetal harm may occur when administered to a pregnant woman

    Lactation

    No data available on the presence of tafamidis in human milk, effect on the breastfed infant, or the effect on milk production

    Tafamidis is present in rat milk; drug may likely be present in human milk

    Adults

    80 mg once daily (Vyndaqel); 61 mg once daily (Vyndamax).

    Geriatric

    80 mg once daily (Vyndaqel); 61 mg once daily (Vyndamax).

    Adolescents

    Safety and efficacy have not been established.

    Children

    Safety and efficacy have not been established.

    Infants

    Safety and efficacy have not been established.

    Neonates

    Safety and efficacy have not been established.

    Tafamidis

    capsule

    • 61mg